Original Research

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis

Fragoulakis VF, Pallis AG, Kaitelidou DK, Maniadakis NM, Georgoulias VG

Lung Cancer: Targets and Therapy 2012, 3:43-51

Published Date: 16 July 2012